Evidence map›Paper›PMID 21898493›Full record

GuidelineHepatology (Baltimore, Md.)2011

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Marc G Ghany, David R Nelson, Doris B Strader, David L Thomas, Leonard B Seeff, American Association for Study of Liver Diseases

Abstract readComparative StudyPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Hepatology (Baltimore, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 381 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
381citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

381 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2014
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

321 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Marc G GhanyLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1800, USA. marcg@intra.niddk.nih.gov
David R Nelson
Doris B Strader
David L Thomas
Leonard B Seeff
American Association for Study of Liver Diseases

Funding

Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis CZIADK075009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2009 to 2025
$7.2M
A Multidisciplinary and Translational Approach to Hepatobiliary MalignancyK24CA139570 · NCI · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2010 to 2014
$887k
NCI NIH HHS K24 CA139570
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsDrug Resistance, ViralFemaleGenotypeHepacivirusHepatitis C, ChronicHumansMaleOligopeptidesPrognosisProlineProtease InhibitorsRandomized Controlled Trials as TopicRecurrenceRisk AssessmentSocieties, MedicalAntiviral AgentsN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideOligopeptidesProlineProtease Inhibitorstelaprevir

Identifiers

PMID21898493
PMCPMC3229841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.